Page last updated: 2024-12-05

oxamniquine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxamniquine is an antiparasitic drug used to treat schistosomiasis, a parasitic disease caused by Schistosoma worms. It is a synthetic derivative of the natural product lucanthone, and is thought to act by inhibiting the enzyme phosphodiesterase, which is involved in the life cycle of the parasite. The drug was developed by the pharmaceutical company Hoechst, and was first introduced in 1976. Oxamniquine is effective in treating both acute and chronic schistosomiasis. However, it has a number of side effects, including gastrointestinal problems, dizziness, and headaches. Oxamniquine is now used less frequently because of the development of other more effective and safer anti-schistosomal drugs, such as praziquantel. Despite the development of other drugs, oxamniquine is still studied for its potential to treat other parasitic diseases, such as filariasis. Oxamniquine remains an important tool in the fight against schistosomiasis, particularly in areas where other drugs are not readily available.'

Oxamniquine: An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martindale, The Extra Pharmacopoeia, 31st ed, p121) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxamniquine : A racemate comprising equimolar amounts of (R)- and (S)-oxamniquine. An anthelmintic, it is administered orally for the treatment of schistomiasis caused by Schistosoma mansoni (but not by other Schistosoma species); intramuscular administration is no longer used as it causes severe pain at the injection site. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

{2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol : A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4612
CHEMBL ID847
CHEBI ID78416
CHEBI ID7819
SCHEMBL ID44921
MeSH IDM0015634

Synonyms (116)

Synonym
6-hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline
oxamniquinum [inn-latin]
1,2,3,4-tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol
2-((isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydro-6-quinolinemethanol
1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol
6-quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-
einecs 244-556-4
6-quinolinemethanol, 1,2,3,4-tetrahydro-2-((isopropylamino)methyl)-7-nitro-
oxamniquina [inn-spanish]
ccris 4113
nsc 352888
hsdb 6510
oxaminiquine
brn 0485597
(2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol
uk-4271
6-quinolinemethanol,2,3,4-tetrahydro-2-[(isopropylamino)methyl]-7-nitro-
uk 4271
2-(isopropylaminomethyl)-7-nitro-1,3,4-tetrahydroquinoline-6-methanol
vansil
nsc-352888
6-quinolinemethanol,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-
nsc352888
mls000756891 ,
1,3,4-tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol
uk 4261
mansil
PRESTWICK2_001026
NCGC00016755-01
cas-21738-42-1
[2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl]methanol
{2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol
C07341
oxamniquine
21738-42-1
DB01096
mansil (tn)
oxamniquine (usan/inn)
vansil (tn)
D00460
smr000528982
PRESTWICK0_001026
PRESTWICK1_001026
SPBIO_003072
CHEMBL847
uk-4261
chebi:78416 ,
oxamniquinum
HMS1571M13
[7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol
dtxcid803398
tox21_110593
dtxsid3023398 ,
HMS2230H11
0o977r722d ,
oxamniquine [usan:usp:inn:ban]
5-22-11-00475 (beilstein handbook reference)
oxamniquina
unii-0o977r722d
1,2,3,4-tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol
HMS3371N13
oxamniquine [vandf]
oxamniquine [mi]
oxamniquine [usan]
oxamniquine [who-dd]
oxamniquine [mart.]
oxamniquine [inn]
oxamniquinum [who-ip latin]
oxamniquine [orange book]
oxamniquine [who-ip]
oxamniquine [hsdb]
(+/-)-oxamniquine
SCHEMBL44921
(2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydro-6-quinolinyl)methanol #
XCGYUJZMCCFSRP-UHFFFAOYSA-N
6-quinolinemethanol, 1,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-
2-(isopropylaminomethyl)-7-nitro-1,2,3,4-tetrahydroquinoline-6-methanol
(7-nitro-2-{[(propan-2-yl)amino]methyl}-1,2,3,4-tetrahydroquinolin-6-yl)methanol
{2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydro-6-quinolinyl}methanol
unii-7gij138h3k
40247-39-0
unii-00bcy677ot
SR-01000765728-2
sr-01000765728
6-quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-, (-)-
119678-90-9
(+)-oxamniquine
7GIJ138H3K ,
oxamniquine, (+)-
00BCY677OT ,
6-quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-, (+)-
oxamniquine, (-)-
119678-89-6
CS-0002596
HY-10416
Q682497
oxamniquine(200mg)discontinued
(2-((isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol
EN300-17960854
AKOS040742353
(+-)-1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol
oxamniquina (inn-spanish)
6-hydroxymethyl-2-isopropylaminomethyl-7-nitro -1,2,3,4-tetrahydroquinoline
rac-oxamniquine
1,2,3,4-tetrahydro-2-((isopropylaminoi)methyl)-7-nitro-6-quinolinemethanol
(+-)-(2-((isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol
chebi:7819
oxamniquine (usan:usp:inn:ban)
p02ba02
(+-)-6-hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline
oxamniquine (mart.)
rac-1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol
1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6- quinolinemethanol
rac-6-hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline
rac-(2-((isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol
oxamniquinum (inn-latin)

Research Excerpts

Overview

Oxamniquine is a pro-drug converted into its active form by schistosomal sulfotransferase. It is used clinically in the treatment of infections due to Schistosoma mansoni.

ExcerptReferenceRelevance
"Oxamniquine is an antiparasitic agent commonly used in therapeutics against Schistosoma mansoni. "( Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs.
Brandt, CA; da Silveira, MA; de Souza Menezes, CM; Filho, RP; Paula, GA; Pinto, PL, 2007
)
2.04
"Oxamniquine is a pro-drug converted into its active form by schistosomal sulfotransferase."( Schistosomal Sulfotransferase Interaction with Oxamniquine Involves Hybrid Mechanism of Induced-fit and Conformational Selection.
Ezebuo, FC; Uzochukwu, IC, 2020
)
1.54
"Oxamniquine is a potent schistosomicide used clinically in the treatment of infections due to Schistosoma mansoni. "( Preliminary investigations of some derivatives of oxamniquine.
Karekezi, CW; Lucas, PD; Marples, BA; Salt, WG, 1995
)
1.99
"Oxamniquine proved to be an efficient drug for the treatment of Schistosoma mansoni in adults. "( A preliminary report on the treatment of intestinal schistosomiasis with oxamniquine.
Shafei, AZ, 1979
)
1.93

Effects

ExcerptReferenceRelevance
"Oxamniquine has now been in general use for 11 years for the treatment of schistosomiasis mansoni. "( A review of clinical experience with oxamniquine.
Foster, R, 1987
)
1.99

Actions

ExcerptReferenceRelevance
"Oxamniquine produced an increase in the tonus and spontaneous activity of the worm."( Schistosoma mansoni: new method for recording motor activity in vitro.
de Moura, RS; Rozental, R, 1983
)
0.99

Treatment

Oxamniquine treatment of S. schistosomiasis patients is followed by an improvement of a Th1 response in vitro. Treatment with oxamniquin resulted in near total eradication of the disease.

ExcerptReferenceRelevance
"Oxamniquine-treated at day 70 and measured at day 160 7.9+/-0.4; oxamniquine-treated at day 160 and measured at day 250, 7.6+/-1.7."( On the increase of portal pressure during the acute and chronic phases of murine schistosomiasis mansoni and its reversibility after treatment with oxamniquine.
Aguiar, BG; Coelho, PM; Costa, G; Cunha-Melo, JR, 2003
)
1.24
"The oxamniquine treatment of acute schistosomiasis patients is followed by an improvement of a Th1 response in vitro."( Treatment of human acute schistosomiasis with oxamniquine induces an increase in interferon-gamma response to Schistosoma mansoni antigens.
Abath, FG; Aroucha, ML; Barbosa, CS; Carvalho Júnior, LB; de Souza, JR; Domingues, AL; Miranda, PJ; Montenegro, SM; Morais, CN, 2007
)
1.08
"Oxamniquine-treated worms required 4-8 days for these effects to be apparent."( Temporal differences in praziquantel- and oxamniquine-induced tegumental damage to adult Schistosoma mansoni: implications for drug-antibody synergy.
Fallon, PG; Fookes, RE; Wharton, GA, 1996
)
1.28
"Oxamniquine treatment of infected mice inhibited such alterations."( Experimental schistosomiasis mansoni: electrophoretic studies on serum proteins before and after administration of oxamniquine.
Amin, AM; Mikhail, EG, 1989
)
1.21
"In oxamniquine-treated mice there was a delayed migration from the skin relative to controls and fewer parasites in total appeared to reach the lungs."( Induction of resistance to Schistosoma mansoni in mice by chemotherapy: migration of schistosomula in primary and challenge infections.
Bickle, QD; Mastin, AJ; Wilson, RA, 1985
)
0.78
"Treatment with oxamniquine was made with 100 mg/kg.b.w., 25 mg/kg.b.w."( Immunostimulation as adjuvant for the chemotherapy of experimental schistosomiasis.
Andrade, ZA; Silva, LM,
)
0.47
"Treatment with oxamniquine administered during the acute phase led to a decrease in thymidine incorporation rate 160 days after infection (90 days after treatment) and 24 hours after hepatectomy."( Hepatic regeneration after partial hepatectomy in mice infected with Schistosoma mansoni, at the acute and chronic phases of the disease.
Aguiar, BG; Coelho, PM; Costa, G; Cunha-Melo, JR; Gonçalves, SC; Toppa, NH,
)
0.47
"Treatment with oxamniquine resulted in near total eradication of S."( Evaluation of hepatic fibrosis after oxamniquine therapy of murine schistosomiasis.
Girgis, NI; Ishak, EA; Khayyal, MT; Mansour, MM; Morcos, SH; Saleh, S, 1992
)
0.9

Pharmacokinetics

ExcerptReferenceRelevance
" There were no significant differences in oxamniquine mean area under the plasma concentration time curve (AUC), plasma half life (T1/2), or time to reach peak concentration (Tmax)."( Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan.
Daneshmend, TK; Homeida, MA, 1987
)
1.98
" The pharmacokinetic parameters (mean +/- SD) in the rabbit and rat, respectively, were as follows: plasma clearance, 65."( Pharmacokinetics of oxamniquine in rabbit and rat.
Indalo, AA; Kokwaro, GO; Taylor, G,
)
0.45

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The higher dosage requirements for oxamniquine in the Sudan are unlikely to be due to lower plasma concentrations amongst the Sudanese. The method was developed to study serum concentration profiles of different dosage forms.

ExcerptRelevanceReference
" A dosage schedule of hycanthone which was too small to have any significant chemotherapeutic effect in mice (3 X 3 mg/kg) was sufficient to induce a statistically highly significant incidence of micronodular lesions and of precancerous nodules."( Long-term hepatocellular effects of hycanthone and of two other anti-Schistosomal drugs in mice infected with Schistosoma mansoni.
Bueding, E; Haese, WH, 1976
)
0.26
" Several dosage regimens have been tried but a total dose of 40 mg/kg over two days in two equally divided doses has been found to have an effective therapeutic action on the polypi, with correction of the anaemia, hypoalbuminaemia and serum iron."( Chemotherapy of schistosomal colonic polyposis with oxamniquine.
Abaza, HH; Hammouda, N; Rabbo, HA; Shafei, AZ, 1978
)
0.51
" The method was developed to study serum concentration profiles of different dosage forms of oxamniquine."( Determination of oxamniquine in serum.
Wood, PR; Woolhouse, NM, 1977
)
0.82
" These results suggested that a combination solid dosage form was feasible."( Physiochemical interactions of praziquantel, oxamniquine and tablet excipients.
Ahmed, SM; Prankerd, RJ, 1992
)
0.54
" The reduction in adult worm recovery after dosing with 50 mg/kg oxamniquine was 89."( Effects of praziquantel and oxamniquine on a Saudi Arabian strain of Schistosoma mansoni in mice.
Banaja, AA; Ghandour, AM; Shalaby, IM, 1990
)
0.81
"Brain and plasma concentrations of oxaminiquine were determined following intravenous dosing (15 mg kg-1) in female Wistar rats."( Partitioning of oxaminiquine into brain tissue following intravenous administration to female Wistar rats.
Kokwaro, GO; Taylor, G, 1990
)
0.28
" The higher dosage requirements for oxamniquine in the Sudan are unlikely to be due to lower plasma concentrations amongst the Sudanese."( Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan.
Daneshmend, TK; Homeida, MA, 1987
)
1.99
" Dosage varies with the geographical origin of the parasites due to different susceptibilities of local strains, and the appropriate regimen can be expected to cure over 80% of patients and reduce egg excretion in others by over 90%."( A review of clinical experience with oxamniquine.
Foster, R, 1987
)
0.55
" Isolates from infected children were passaged into mice and dosed with oxamniquine."( Tolerance of Kenyan Schistosoma mansoni to oxamniquine.
Bruce, JI; Coles, GC; Katz, N; Kinoti, GK; Mutahi, WT, 1987
)
0.77
"The advent of several new column materials for the resolution of chiral compounds in high-performance liquid chromatography has opened up new possibilities for the analysis of drug enantiomers both in the dosage form and in bioanalytical studies."( Computer-aided optimisation of drug enantiomer separation in chiral high-performance liquid chromatography.
Clark, BJ; Fell, AF; Mama, JE; Noctor, TA, 1988
)
0.27
" At the maximum dosage after 24 h of permanent contact with the cells (extreme, non-physiological conditions), cytolysis did not exceed 30%."( Action of new organometallic complexes against Leishmania donovani.
Craciunescu, D; Lazuen, J; Mesa-Valle, CM; Moraleda, V; Osuna, A, 1997
)
0.3
" This technique provided conditions for the separation of the active ingredient from the dosage form by extraction in methanol."( Determination of oxamniquine in capsules by HPLC.
Almeida, AE; Gremião, MP; Pierri, EG, 2001
)
0.65
"Further research will help find the optimal dosing regimen of both these drugs in children."( Drugs for treating Schistosoma mansoni infection.
Danso-Appiah, A; Donegan, S; Olliaro, PL; Sinclair, D; Utzinger, J, 2013
)
0.39
" These findings have important implications for the design, syntheses, and dosing of new OXA-based antischistosomal compounds."( Structural and Functional Characterization of the Enantiomers of the Antischistosomal Drug Oxamniquine.
Anderson, TJ; Basso, A; Cao, X; Cioli, D; Donati, E; Guidi, A; Hart, PJ; Holloway, SP; LoVerde, PT; Pica-Mattoccia, L; Polcaro, CM; Rugel, AR; Taylor, AB, 2015
)
0.64
" In silico models were used to predict murine dosing to recapitulate human conditions for OXA portal concentration and time course."( Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments.
Alwan, S; Cameron, MD; Khan, S; LoVerde, PT; McHardy, SF; Toth, K, 2023
)
1.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
aromatic primary alcoholAny primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency89.12510.044717.8581100.0000AID485294
GLS proteinHomo sapiens (human)Potency19.95260.35487.935539.8107AID624170
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
Guanine nucleotide-binding protein GHomo sapiens (human)Potency12.58931.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1132881Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 52 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID293105Antiparasitic activity against Schistosoma mansoni BH cercareae infected Swiss mouse assessed as average number of eggs at 2 stage after 10 days by oogram test2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1422786Antischistosomal activity against Schistosoma haematobium infected in golden syrian hamster assessed as worm killing at 143 uM pretreated for 45 mins followed by compound washout measured after 14 days2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Design, Synthesis, and Characterization of Novel Small Molecules as Broad Range Antischistosomal Agents.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID293107Antiparasitic activity against Schistosoma mansoni BH cercareae infected Swiss mouse assessed as average number of eggs at 1 stage after 20 days by oogram test2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1446910Inhibition of Schistosoma mansoni KDAC8 at 30 uM using (FAM)-labeled peptide as substrate after 60 mins by microfluidic assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID202233Percent [3H]uridine incorporation relative to controls for a dose of 50 ug/mL against hycanthone-resistant schistosomes1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Studies on some derivatives of oxamniquine.
AID1132883Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 13 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID293111Antiparasitic activity against Schistosoma mansoni BH cercareae infected Swiss mouse as total numbers of worms after 20 days by mesenteric veins perfusion technique2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs.
AID202229Percent [3H]uridine incorporation relative to controls for a dose of 100 ug/mL against hycanthone-resistant schistosomes1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Studies on some derivatives of oxamniquine.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1453214Antiparasitic activity against Schistosoma mansoni in patient assessed as reduction in eggs per gram of rectal mucosa at 10 mg/kg/day bid measured up to day 180 post dose relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID293110Antiparasitic activity against Schistosoma mansoni BH cercareae infected Swiss mouse assessed as total number of worms after 10 days by mesenteric veins perfusion technique2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs.
AID1422787Antischistosomal activity against Schistosoma japonicum infected in golden syrian hamster assessed as worm killing at 143 uM pretreated for 45 mins followed by compound washout measured after 14 days2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Design, Synthesis, and Characterization of Novel Small Molecules as Broad Range Antischistosomal Agents.
AID202228Percent [3H]uridine incorporation relative to control at 50 ug/mL against hycanthone-sensitive schistosomes (% worms surviving in culture)1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Studies on some derivatives of oxamniquine.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID293109Antiparasitic activity against Schistosoma mansoni BH cercareae infected Swiss mouse assessed as average number of eggs at 3 stage after 20 days by oogram test2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs.
AID1446908Inhibition of human KDAC6 expressed in baculovirus expression system at 30 uM using FITC-Histone 4 acetylated peptide as substrate after 60 mins by microfluidic assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
AID1132880Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 104 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1453210Drug excretion in human urine at 15 mg/kg, po2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1453209Cmax in human at 15 mg/kg, po2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID202231Percent [3H]uridine incorporation relative to controls for a dose of 100 ug/mL against hycanthone-sensitive schistosomes (% warms surviving in culture).. 1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Studies on some derivatives of oxamniquine.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1752690Antischistosomal activity against Schistosoma mansoni infected in NMRI mouse assessed as worm burden reduction at 100 mg/kg, po administered as single dose relative to control2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1446907Inhibition of full length human C-terminal His-tagged KDAC3/N-terminal GST-tagged human NCOR2 (395 to 489 residues) expressed in baculovirus expression system at 30 uM using FITC-p53 acetylated peptide as substrate after 60 mins by microfluidic assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
AID293108Antiparasitic activity against Schistosoma mansoni BH cercareae infected Swiss mouse assessed as average number of eggs at 2 stage after 20 days by oogram test2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID293106Antiparasitic activity against Schistosoma mansoni BH cercareae infected Swiss mouse assessed as average number of eggs at 3 stage after 10 days by oogram test2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs.
AID1446909Inhibition of full length human C-terminal His-tagged KDAC8 expressed in baculovirus expression system at 30 uM using (FAM)-labeled peptide as substrate after 60 mins by microfluidic assay relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
AID1453208Elimination half life in human at 15 mg/kg, po2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID293104Antiparasitic activity against Schistosoma mansoni BH cercareae infected Swiss mouse assessed as average number of eggs at 1 stage after 10 days by oogram test2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs.
AID1453212Antiparasitic activity against Schistosoma mansoni in patient assessed as cure rate by measuring reduction in eggs in stool at 10 mg/kg/day bid measured up to day 180 post dose relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1446906Inhibition of full length human C-terminal FLAG/His-tagged KDAC1 expressed in baculovirus expression system at 30 uM using substrate A after 60 mins by microfluidic assay relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1422785Antischistosomal activity against Schistosoma mansoni infected in golden syrian hamster assessed as worm killing at 143 uM pretreated for 45 mins followed by compound washout measured after 14 days2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Design, Synthesis, and Characterization of Novel Small Molecules as Broad Range Antischistosomal Agents.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (349)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990209 (59.89)18.7374
1990's55 (15.76)18.2507
2000's43 (12.32)29.6817
2010's29 (8.31)24.3611
2020's13 (3.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.64 (24.57)
Research Supply Index6.25 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index60.73 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials52 (11.16%)5.53%
Reviews28 (6.01%)6.00%
Case Studies31 (6.65%)4.05%
Observational0 (0.00%)0.25%
Other355 (76.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]